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Tuberculosis (TB) is the most common comorbidity and the leading cause of death
among HIV-infected individuals. Although the combined antiretroviral therapy (cART)
during TB treatment improves the survival of TB/HIV patients, the occurrence of immune
reconstitution inflammatory syndrome (IRIS) in some patients poses clinical and scientific
challenges. This work aimed to evaluate blood innate lymphocytes during therapeutic
intervention for both diseases and their implications for the onset of IRIS. Natural killer
(NK) cells, invariant NKT cells (iNKT), γδ T cell subsets, and in vitro NK functional activity
were characterized by multiparametric flow cytometry in the following groups: 33 TB/HIV
patients (four with paradoxical IRIS), 27 TB and 25 HIV mono-infected subjects (prior
to initiation of TB treatment and/or cART and during clinical follow-up to 24 weeks),
and 25 healthy controls (HC). Concerning the NK cell repertoire, several activation and
inhibitory receptors were skewed in the TB/HIV patients compared to those in the other
groups, especially the HCs. Significantly higher expression of CD158a (p = 0.025),
NKp80 (p= 0.033), and NKG2C (p= 0.0076) receptors was detected in the TB/HIV IRIS
patients than in the non-IRIS patients. Although more NK degranulation was observed
in the TB/HIV patients than in the other groups, the therapeutic intervention did not
alter the frequency during follow-up (weeks 2–24). A higher frequency of the γδ T cell
population was observed in the TB/HIV patients with inversion of the Vδ2+/Vδ2− ratio,
especially for those presenting pulmonary TB, suggesting an expansion of particular γδ
T subsets during TB/HIV co-infection. In conclusion, HIV infection impacts the frequency
of circulating NK cells and γδ T cell subsets in TB/HIV patients. Important modifications
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of the NK cell repertoire were observed after anti-TB treatment (week 2) but not during
the cART/TB follow-up (weeks 6–24). An increase of CD161+ NK cells was related to
an unfavorable outcome. Despite the low number of cases, a more preserved NK cell
profile was detected in IRIS patients previous to treatment, suggesting a role for these
cells in IRIS onset. Longitudinal evaluation of the NK repertoire showed the impact of TB
treatment and implicated these cells in TB pathogenesis in TB/HIV co-infected patients.
Keywords: TB/HIV Co-infection, NK cell repertoire, IRIS, innate immune cells, clinical outcomes
INTRODUCTION
Tuberculosis (TB) is one of the world’s deadliest diseases
and affects ∼10.0 million people worldwide. A total of 1.3
million deaths occurred in 2017, and almost one-fourth of the
global population is infected with the infectious agent of TB,
Mycobacterium tuberculosis (Mtb) (1). TB is a leading killer
of HIV-infected people (TB/HIV co-infection) worldwide (2).
Brazil is a World Health Organization high-burden country for
TB and TB/HIV-associated comorbidities (1). In 2017, almost
70.0 thousand TB cases were registered in the country, of
which 6,501 (∼9.4%) were TB/HIV cases. A total of 9.4% of
these cases occurred in the city of Rio de Janeiro, which is
ranked as the second Brazilian state capital in terms of the
number of TB/HIV cases and is considered a TB-endemic
region (3–5). Indeed, estimates from 2016 showed a higher TB
incidence rate in Rio de Janeiro city than the national incidence
(99 vs. 33.5 TB cases/100,000 hab) (3–5). TB/HIV co-infection
poses enormous clinical, scientific, and public health challenges.
Although the use of combined antiretroviral therapy (cART)
during TB treatment improves patient survival, particularly
by restoring immune functions, simultaneous management of
cART and anti-TB drugs is not easy due to pharmacological
interactions. Moreover, the appearance of an inflammatory
syndrome called immune reconstitution inflammatory syndrome
(IRIS) in some patients and early mortality are adverse events
of cART initiation and represent challenges for the management
of TB/HIV patient care (6, 7). IRIS has been associated with
lower CD4+ T cell counts at cART initiation followed by a
dramatic improvement in these cell counts and a rapid plasma
viral load decay that lead to partial restoration of overall immune
functions, and the presence of opportunistic pathogens (8–
11); however, the immunopathogenesis of this syndrome and
the major clinical and laboratory factors associated with IRIS
onset are not clearly understood (12). In TB/HIV IRIS patients,
elevated concentrations of proinflammatory serum mediators
have been detected at IRIS onset, including C-reactive protein
and cytokines, such as IL-6, IL-12, and TNF (13–15). Following
cART initiation, recovery of CD4 Th1 responses to mycobacterial
antigens is reported, and these increased responses have been
associated with IRIS (16–18). Indeed, in a previous study by
our group, an increase in immune responses was observed
in TB/HIV IRIS patients compared with those of non-IRIS
patients, as was a marked increase in IFN-γ production by T
cells from IRIS patients in response to PPD and other Mtb
antigens (19).
Given their importance in antigen processing and pathogen
trafficking, cells of the innate immune system are a focus of
increasing interest in IRIS physiopathology. γδ T cells appear to
play a predominant role against Mtb infection, and one study
demonstrated reduced numbers of inhibitory natural killer (NK)
receptors on mycobacteria-specific Vδ2+ γδ T cells in TB/HIV
IRIS patients (17). Moreover, studies have examined NK cell
function in the development of IRIS among TB/HIV patients.
In a study of unmasking IRIS, these cells were found to express
increased levels of activation markers (20). In a longitudinal
study with a TB/HIV co-infected group in Cambodia, NK cells
isolated from paradoxical IRIS patients had higher expression
of the degranulation marker CD107a than those of non-IRIS
patients prior to IRIS onset at a time point 2 weeks after
initiating TB treatment but before starting cART (21). The
authors hypothesized that increased NK cell-mediated lysis
of Mtb-infected cells might increase the antigen load and
the risk of IRIS occurrence. Therefore, the physiopathology
of TB/HIV coinfection and the occurrence of IRIS might
be explained by an exaggerated innate immune response,
implicating the participation of different players as Toll-like
receptors, inflammasomes, NK cells, monocytes/macrophages,
neutrophils, cytokines, among others (21–26).
Moreover, among TB patients, HIV infection is a risk factor
for extrapulmonary TB, which sometimes require a high index of
suspicion for diagnosis. Although TB is acquired by inhalation
of contaminated droplets, it can produce disease in any organ
system in addition to the lungs, which are usually the initial
site of infection. In the context of TB/HIV co-infection, an
increase in the number of reported cases of extrapulmonary
TB is observed, accounting for ∼20% of TB cases in HIV-
uninfected patients and 53–62% of TB cases among HIV-infected
patients (27). In our previous studies, ∼56% of extrapulmonary
TB cases were registered in our cohort of TB/HIV patients,
including disseminated cases (19, 28). Although the association
between HIV and overall TB (including pulmonary TB) is well-
characterized (29), the relationship between extrapulmonary TB
andHIV is less clear; the mechanisms related to the escape ofMtb
to TB sites out of the lungs are not yet fully clarified, although
extrapulmonary TB is very likely due to the reduction of CD4+
T cell counts in HIV-infected patients, since CD4+ T-helper cells
are important for controlling ofMtb infection (30–34).
In this scenario, we hypothesized that the association between
the exaggerated responses of NK cells before TB treatment and
cART and the increased risk of IRIS after starting both therapies,
as observed in the TB/HIV patients from Cambodia (21), would
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also be found in populations with different genetic backgrounds,
such as patients from Rio de Janeiro city, Brazil. We also
hypothesized a differential implication of innate immunological
parameters in the pathogenesis of extrapulmonary TB, affecting
lymph nodes and disseminated TB cases. Therefore, this
study aimed to explore the implications of innate immune
responses, specifically NK cell responses, in the evolution of
TB/HIV co-infection.
METHODS AND PATIENTS
Study Population
The primary study population consisted of 33 HIV-infected
patients diagnosed with TB (TB/HIV) who started cART 2 weeks
(W2) after TB treatment according to the Brazilian Guidelines for
HIV/AIDS Treatment and the National Tuberculosis Program
(Ministry of Health) at the time of the study (35, 36).
Briefly, 4-drugs TB regimen containing rifampicin, isoniazid,
pyrazinamide, and ethambutol, followed by the first line HIV
treatment with two nucleoside reverse transcriptase inhibitors
(NRTI) + non-nucleoside reverse transcriptase inhibitors
(NNRTI) (35–37). Tuberculosis diagnosis was made when
suggestive clinical symptoms, and radiological findings were
present. In some cases, microbiological methods confirmed the
diagnosis: Ziehl-Neelsen staining for the detection of acid-
fast bacilli in sputum smears and biopsy specimens, Xpert
MTB/RIF R© in sputum for MTB and rifampicin resistance
detection, mycobacteria culture of sputum, and biopsy samples
in Löwenstein-Jensen medium and/or Mycobacteria Growth
Indicator Tube (MGIT) (36). HIV infection was determined
by rapid test and confirmed by conventional serology testing
and western blot, and then, molecular detection of RNA viral
load (35). As inclusion criteria, the TB/HIV patients were
naïve for HIV drugs and presented CD4+ T cell counts below
200 cells/mm3. The TB/HIV patients were evaluated at the
introduction of anti-TB therapy at the baseline visit (D0), at
the initiation of cART (W2) and during the clinical follow-
up visits at weeks 6, 10, 14, and 24. Four TB/HIV patients
developed paradoxical IRIS defined as a documented clinical
worsening of TB signs or symptoms during anti-TB treatment,
after cART initiation, not explained by any other diseases or
by an adverse effect of drug therapy; lymph node enlargement
with inflammatory signs temporally related to cART introduction
was considered IRIS in this study (37–39). Each case of IRIS
was validated in this study by the members of the clinical
coordination team to discard opportunistic disease diagnosis,
drug-resistant TB, low adherence, or adverse effects of cART.
The TB/HIV patients were also analyzed according to their
TB clinical presentations as pulmonary (PTB), lymph node TB
(LNTB), and disseminated TB (DTB) (when two non-contiguous
sites were affected) (37). Moreover, in the context of clinical
outcomes, the patient outcomes were evaluated as favorable
(TB treatment responders) or unfavorable (death) at the end
(usually 6 months) of TB therapy under cART. In parallel to
the TB/HIV patients, three control groups were also studied:
HIV mono-infected subjects (HIV; n = 25), who were evaluated
previous to cART; HIV-seronegative TB patients (TB; n = 27),
who were evaluated previous to TB treatment; and volunteer
healthy controls (HC, n = 25). The diagnosis of HIV infection
was discarded by conventional serology and HIV RNA viral
quantification in TB and HC groups, while TB infection was
ruled out by the clinic and radiological examination in HIV and
HC groups. However, if healthy participants had any sign or
symptom, Xpert MTB/RIF R© in sputum for MTB and rifampicin
resistance detection and mycobacteria culture of sputum samples
in Löwenstein-Jensen medium and/or MGIT were performed.
All participants, including the HC, who agreed to participate in
this study were enrolled after signing the informed consent form.
Participant recruitment started in August 2014 and extended
until December 2016 at the Instituto Nacional de Infectologia
Evandro Chagas (INI), which is the clinical research unit for adult
care in infectious diseases of the Oswaldo Cruz Foundation, and
at the Hospital Geral de Nova Iguacu (HGNI), which is a general
hospital from the Brazilian Ministry of Health. HGNI is located
in the outskirts of Rio de Janeiro, and is a referral center for HIV
and TB care in 13 municipalities. This protocol was approved by
the local institutional Ethics Committee (Instituto Oswaldo Cruz
Research Ethics Committee) and the Brazilian National Ethics
Committee—CONEP (CAAE: 04514012.1.1001.5248).
Phenotypic Innate Lymphoid Cell Studies
NK cells, invariant NKT cells (iNKT) and γδ T cell subsets were
characterized from fresh whole blood through multiparametric
flow cytometry (Gallios flow cytometer and Kaluza Version 3.0
analysis software, Beckman-Coulter, Kendon, FL, USA). NK cells
were identified as CD3−CD56+/−CD16+/− within the gated
lymphocyte population previously defined in the FSC/SSC dot
plot. The same strategy was used to define the iNKT cells,
which were identified using the monoclonal antibody 6B11,
specific to the conserved CDR3 region of the canonical hallmark
T cell receptor (TCR)-invariant chain Vα24Jα18 (40–42) and
defined as CD3+CD56+/−Vα24Jα18+ lymphocytes, as detailed
in the Supplementary Figure 1A. In its turn, the γδ T cell
subsets were identified as CD3+CD56+Panγδ+ lymphocytes
coexpressing or not the Vδ2 chain. The NK repertoire receptors
were evaluated using monoclonal antibodies based on the CAPRI
NK study results (21), including the KIR family (CD158a,
CD158b1/b2,j, CD158d, CD158e, CD158e1/e2, and CD158i),
NCR receptors (NKp30, NKp44, and NKp46), NKG family (2A,
2C, and 2D), CD94, CD85j, CD160, CD161, NKp80, DNAM-1,
CD244, and activation marker CD69 (from Beckman-Coulter;
BD Biosciences, San Jose, CA, USA; R&D Systems, Minneapolis,
MN, USA; and BioLegend, San Diego, CA, USA).
Cytokine Assays and Cytolytic NK Cell
Activity
CD107a expression on NK cells and the intracellular
cytokine staining (ICS)-based assay were used to measure
cytotoxic activity (degranulation) and cytokine expression as
described previously with some modifications (21, 43). Briefly,
mononuclear cells (PBMCs) isolated from fresh whole blood
were incubated overnight at 37◦C with 5% CO2 at 1:1 ratio with
the K562 cell line, which was used as target cells, in the presence
of a CD107a monoclonal antibody, brefeldin A (5µg/mL;
Frontiers in Immunology | www.frontiersin.org 3 August 2019 | Volume 10 | Article 1800
Giacoia-Gripp et al. NK Changes in TB/HIV Co-infection
Sigma-Aldrich, St. Louis, MO, USA) and monensin (6µg/mL;
Sigma-Aldrich), which were added concomitantly to the cells.
Spontaneous basal degranulation and cytokine production were
measured by incubating PBMCs under the same conditions
without target cells. After incubation, anti-CD3, anti-CD56,
and anti-CD16 were added, followed by antibodies for the
ICS-based assay (IFN-γ, TNF, TGF-β, and IL-10; Beckman-
Coulter and BD Biosciences). These evaluations were assessed by
multiparametric flow cytometry using the XL-MCL and Gallios
equipment from Beckman-Coulter.
Statistical Analysis
The HIV viral load and immunological parameters, including
CD4+ T cells, NK cells (receptor repertoire, CD107a expression,
and cytokine levels), iNKT and the γδ T innate cell subsets, were
assessed in the TB/HIV patients during follow-up and in the
control group at baseline (D0). Descriptive analyses of clinical
and demographic characteristics were performed for the patients
and controls. The Wilcoxon t-test, Mann-Whitney U test, and
Kruskal-Wallis test were used to evaluate quantitative variables,
whereas Fisher’s exact test and Pearson’s chi-square test were
used for categorical variables. A p-value < 0.05 was considered
significant. The slope of the CD4+ T cell absolute count and HIV
viral load was estimated by a non-linear least squares method for
a five-parameter sigmoidal curve (44). Briefly, the slope indicates
the growth/degrowth rate of an indicator during the “window
of linearity,” which is the highest linearity region of the curve.
The maximum and minimum points of the second derivate
curve were used as boundaries for this region. The statistical
analysis was performed using the Stata software version 11.0
(STATA Corp. College Station, TX, USA), and the GraphPad
Prism version 6.0 software (GraphPad Software, La Jolla, CA,
USA) was used to generate the graphics. Sigmoidal fitting was
performed using R version 3.0.3 (2014-03-06—“Warm Puppy”).
RESULTS
Demographic Characteristics of the
Studied Groups
The clinical and sociodemographic characteristics obtained from
all participants in the study are presented in Table 1. No
differences in age, gender, race or tuberculosis presentation were
observed in the distribution of participants among the groups,
although a trend for a higher frequency of TB occurrence was
observed for males. The basal CD4+ T cell absolute counts were
extremely low among the TB/HIV and HIV patients compared
to those of the other participants (p = 0.0001). As expected,
the basal CD4/CD8 ratios were also lower among these patients
than in the TB and HC groups (p = 0.0001). Interestingly, the
TB/HIV group presented HIV viral loads that were significantly
higher than those of the HIV group (p = 0.0077). The major TB
presentation was pulmonary regardless of the presence of HIV
coinfection, followed by lymph node TB. Disseminated TB was
diagnosed in 15.1% of the TB/HIV patients, whereas no case
was detected in the TB group. Among the 33 TB/HIV recruited
participants, only 4 (12.1%) developed symptoms consistent
with IRIS after beginning cART, which was in agreement with
the frequency of IRIS observed in our previous studies (28,
45). The IRIS onset was observed from 1–3 weeks after cART
initiation and was clinically diagnosed as defined above. In
general, the patients presented worsening of the signs/symptoms
related to TB, like fever and enlargement of the right or the
left cervical/submandibular lymph nodes, which were either
self-resolving, or the patients were treated with corticoid-based
therapy, such as Prednisone (Supplementary Table 1). At D0,
the IRIS and non-IRIS TB/HIV patients presented similar CD4+
T cell absolute counts (data not shown). Concerning the HIV
viral load, higher levels were observed for the IRIS patients at the
D0 than for the non-IRIS TB/HIV participants (p = 0.0088). As
defined previously, 26 (78.8%) of the 33 TB/HIV patients were
classified as having a favorable outcome, 5 (15.1%) were defined
as having an unfavorable outcome, and outcome information
were missing for 2 (6.1%) at the end of the study follow-up.
Virological and Immune Responses to TB
and/or cART Treatment During Follow-Up
The CD4+ T cells and HIV viral load were also evaluated for the
TB/HIV group at starting TB treatment (D0), at cART initiation
2 weeks later (W2), and during the follow-up visits (W6, 10, 14,
and 24) (Figure 1). The TB/HIV patients showed a significant
increment of CD4+ T cells after the first month of cART (at week
6), and this increase was sustained over the follow-up (Figure 1A;
Slope = 36.59). Notably, a higher slope was detected for the
CD4+ T cell increment for the TB/HIV IRIS patients (Figure 1B;
Slope = 95.53) than for the non-IRIS patients (Figure 1C; Slope
= 24.31), which indicated the higher increase in CD4+ T cell
counts among the IRIS patients. As expected, the HIV viral load
significantly declined from weeks two to six, for which a negative
slope of 0.95 was observed, and this decay was continuous during
the follow-up (Figure 1D). A similar response was observed
when the TB/HIV non-IRIS patients were assessed separately,
implying the development of fast control of HIV replication with
cART in these patients, whereas less prominent control of the
viral load was detected in the IRIS patients (Figure 1E: IRIS Slope
=−0.35, Figure 1F: non-IRIS Slope=−1.01).
Circulating Innate Immune Cells and the
NK Cell Repertoire Profile Before Clinical
Intervention
To characterize the circulating NK, iNKT and γδ T cell profiles,
fresh whole blood samples collected from all participants
were investigated at the D0. The TB/HIV patients presented
a lower frequency of CD56+/−CD16+/−CD3− NK cells
than the healthy controls (p = 0.037) and TB patients (p
= 0.015), showing the negative impact of HIV infection on
circulating NK cells (Figure 2A). Concerning the iNKT cells,
no difference in the frequencies of CD3+CD56+Vα24Jα18+
cells was identified among the TB/HIV patients and the other
groups (Figure 2A). The same scenario was observed when
the CD3+Vα24Jα18+ iNKT population was analyzed among
the groups (Supplementary Figure 1B). Moreover, higher
percentages of circulating γδ T cells were observed in the
TB/HIV patients compared to those of the HC participants (p
= 0.0027; Figure 2A). The frequencies of γδ T cells expressing
the Vδ2 chain (Vδ2+) were decreased in the TB/HIV and
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TABLE 1 | Clinical and sociodemographic characteristics of the TB/HIV, HIV, and TB patients and HC volunteers.
Characteristic TB/HIV
(N = 33)
HIV
(N = 25)
TB
(N = 27)
HC
(N = 25)
P-value*
Age (years), median (IQR) 35 (32–42) 36 (27–43) 36 (27–48) 44 (34–49) 0.1433a
Gender, n (%)
Male 24 (72.7) 17 (68.0) 17 (63.0) 10 (40.0) 0.063b
Female 9 (27.3) 8 (32.0) 10 (37.0) 15 (60.0) –
Race, n (%)
Black 6 (18.2) 4 (16.0) 4 (14.8) 3 (12.0) 0.102c
Brown 16 (48.5) 15 (60.0) 11 (40.7) 9 (36.0) –
White 11 (33.3) 6 (24.0) 12 (44.4) 13 (52.0) –
Site of tuberculosis, n (%)
Pulmonary 20 (60.6) na 20 (74.1) na 0.213c
Lymph node 6 (18.2) na 5 (18.1) na –
Extrapulmonary 2 (6.1) na 2 (7.4) na –
Disseminated 5 (15.1) na – na –
IRIS, n (%)
Yes 4 (12.1) na na na –
No 29 (87.9) na na na –
Clinical outcomes, n (%)e
Favorable 26 (78.8) na 27 (100) na –
Unfavorable 5 (15.5) na – na –
Missed 2 (6.1) na – na
Baseline CD4 (cells/mm3 ), median (IQR) 57 (17–144) 42 (23–139) 745 (537–980) 1118 (872–1,320) 0.0001a
Baseline CD4/CD8 ratio median (IQR) 0.08 (0.04–0.17) 0.11 (0.05–0.19) 1.41 (1.00–2.07) 1.88 (1.57–2.38) 0.0001a
Baseline HIV-1 viral load (log10 copies/ml), median (IQR) 5.64 (5.22–5.88) 5.28 (4.99–5.59) na na 0.0077
d
N, number of cases; IQR, Interquartile ranges (75th−25th percentiles); IRIS, Immune Reconstitution Inflammatory Syndrome; na, not applicable.
aKruskall-Wallis test.
bChi-square test.
cFisher’s exact test.
dMann-Whitney U-test.
eClinical outcomes analysis is only related to TB.
*p < 0.05.
HIV-infected patients compared to those in the HCs and TB
patients. As expected, γδ T cells expressing other Vδ chains
(Vδ2−) were the predominant subset among the TB/HIV and
HIV mono-infected patients, with a very low Vδ2+/Vδ2− ratio
(Figure 2B; p< 0.0001).
Concerning the NK cell repertoire, we tested 20 different
receptors. The results for those presented statistically significant
differences among the TB/HIV patients and the other groups are
depicted in Figure 3. Except for CD158d and CD69, generally,
the TB/HIV patients showed lower frequencies of these selected
NK receptors than the other studied groups. These alterations
targeted important activating and inhibitory molecules
indistinctly and showed the impact of both comorbidities
on the NK cell repertoire. Medians and interquartile ranges
for all investigated receptors for all groups are presented in
Supplementary Table 2.
Analysis of NK Subsets in IRIS Patients
The impacts of the NK subsets on the inflammatory process were
assessed in the TB/HIV IRIS patients despite the low number
of confirmed IRIS cases. Prior to TB treatment, the non-IRIS
patients presented a lower frequency of NK cells than the HC
(p = 0.009), and a trend for a lower frequency compared to that
of the IRIS patients (p = 0.055). Conversely, the IRIS patients
and HCs had more similar NK cell frequencies (Figure 4A).
Interestingly, three NK receptors (NKG2C, NKp80, and CD158a,
Figures 4B–D) were decreased in the non-IRIS patients but were
expressed at similar levels between the IRIS patients and HC.
At IRIS onset, no significant difference was found in the NK
cell subsets between the patients with and without IRIS (data
not shown). Despite the limited number of IRIS cases, these
observations suggest a more preserved NK cell profile among
the IRIS patients, similar to the HC. The iNKT and γδ T cells
were also evaluated, but no significant differences were observed
for these populations between the IRIS and non-IRIS patients at
study entry.
Frequencies of Innate Immune Cells in
TB/HIV Patients According to the TB
Clinical Presentation
The innate lymphocyte subsets were also analyzed in the context
of the TB clinical presentation regardless of the onset of
IRIS. TB/HIV patients with PTB presented higher γδ T cell
frequencies than either the HC (Figure 5A; p = 0.0005) or
TB/HIV patients presenting LNTB (p = 0.022), whereas no
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FIGURE 1 | Blood CD4+ T counts and plasma HIV viral loads in the TB/ HIV patients during follow-up. (A–C) Evolution of CD4+ T cell counts (absolute values) and
(D–F) the HIV viral load (Log10 copies/mL) after starting cART (red arrows) in the TB/HIV (A,D), IRIS (B,E), and non-IRIS (C,F) patients. The results are presented as
the slopes of the CD4+ T cell (cells/mm3 ) increase and HIV viral load (Log10 copies/mL) decrease.
difference was observed in those with DTB (Figure 5A). These
differences were not detected between the TB patients presenting
with PTB and LNTB. A trend for a higher γδ T cell frequency
was observed in the TB/HIV patients compared to that of the TB
patients (Figure 5A; p = 0.056) with PTB. These observations
suggested that γδ T cell expansion occurred in cases of co-
infected patients with PTB presentation. Concerning the NK cell
frequency, a decrease was observed for PTB cases among the
TB/HIV patients compared to that of the HC (p = 0.033) and
the TB patients presenting with PTB (Figure 5B; p= 0.005). The
NKp44+ NK cell frequency tended to be higher in the TB/HIV
patients presenting with PTB than with LNTB, suggesting that
more in vivo activation of NK cells occurred in this group of
patients (Figure 5C; p = 0.056). The same findings were not
observed between the TB PTB and LNTB groups, reinforcing
the role of HIV infection in NK cell activation. No significant
differences were observed in either iNKT cells or other profiles of
NK subsets when they were analyzed according to the TB clinical
presentation (data not shown).
Potential for NK Cell Degranulation and
Cytokine Production
The potential for NK cell degranulation and cytokine production
was also investigated among the groups. NK cell degranulation
was addressed through CD107a expression; the results are
shown in Figure 5. A significantly higher percentage of NK
cells expressing CD107a was observed in the TB/HIV patients
at D0 than among the HIV, TB, and HC groups (Figure 6A).
However, when we analyzed the degranulation capacity of NK
cells according to the development of IRIS, no difference was
observed between the IRIS patients and the other groups.
Moreover, no difference was observed in CD107a-expressing
NK cells in the TB/HIV patients regardless of the TB clinical
presentation (data not shown). We also analyzed CD107a
expression on NK cells under stimulated and non-stimulated
conditions. In vitro stimulation with the target cell line was
able to significantly increase the frequency of CD107a+ NK
cells in all groups compared to that of the non-stimulated
condition (Figure 6B; p < 0.0001). Furthermore, significantly
higher CD107a+ NK cell percentages were detected in the
TB/HIV patients under the non-stimulated condition than in the
other groups, indicating in vivo NK cell activation. Interestingly,
this higher CD107a expression without stimulation was not
observed more frequently in IRIS patients (Figure 6C; p= 0.01).
Both the IRIS and non-IRIS patients had similarly increased
CD107a+ NK cell frequencies when stimulated in vitro by target
cells (Figure 6C).
Intracellular IFN-γ, TNF, TGF-β, and IL-10 cytokine
production by NK cells was assessed after in vitro stimulation
with target cells. As shown in Figure 7A, the TB/HIV patients
presented a decrease in IFN-γ and TNF staining compared to
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FIGURE 2 | NK, iNKT, and γδ T cell subset phenotyping. The NK, iNKT, and
the γδ T cell subsets were analyzed prior to TB treatment and/or cART. The
frequencies of (A) the circulating NK, iNKT (CD3+CD56+ Vα24Jα18+) and γδ
T cell populations, (B) the Vδ2+ and Vδ2− T cell subsets, and the Vδ2+/Vδ2−
ratio for TB patients co-infected with HIV (TB/HIV, n = 33), HIV mono-infected
individuals (HIV, n = 25), TB-only patients (TB, n = 27), and healthy controls
(HC, n = 25) at D0. The results are expressed as the % of total lymphocytes
(A) or γδ T cells (B). Histograms represent the median and interquartiles
(25th−75th percentile) for each group. A dashed line indicates the Vδ2+/Vδ2−
ratio = 1.0. The data were analyzed using the Mann-Whitney U test.
Significant p-values (p < 0.05) are indicated.
that of the HC and the HIV, TB, and HC groups, respectively.
On the other hand, the frequency of TGF-β-producing NK
cells in the TB/HIV group was significantly higher than that in
the HIV mono-infected and TB patients. Despite the very low
frequencies of IL-10+ NK cells observed in all groups, higher
production was observed in TB- and/or HIV-infected patients
compared to that of the HC. No differences were observed when
intracellular cytokine production was compared between the
IRIS and non-IRIS patients (not shown). By contrast, lower
IFN-γ and TNF production were detected in the PTB and LNTB
TB/HIV patients than in the HC (Figure 7B), whereas the PTB
and DTB TB/HIV patients had higher levels of IL-10+ NK cells
than the HC. Furthermore, IFN-γ- and TNF-producing NK
cells were also significantly lower in the LNTB-TB/HIV patients
than in the LNTB-TB and the PTB and LNTB TB/HIV patients,
respectively. No specific TGF-β production profile was observed
regardless of the TB clinical presentation.
Impacts of TB Treatment on the NK
Repertoire
Despite a satisfactory virological response and quantitative
recovery of CD4+ T cells, no significant recovery of circulating
NK, iNKT, and γδ T cells, including the Vδ2+ and Vδ2− subsets,
was detected during the follow-up (data not shown). However,
significant alterations were observed in the NK cell repertoire
after the first 2 weeks of TB treatment (W2) and prior to
cART for almost all receptors, except for NKG2C, which also
presented significant changes throughout the 24 weeks of follow-
up, as presented in Figure 8. Some receptor frequencies were
also altered with cART, including CD158e1/e2, which presented
significant changes in its frequency only after cART initiation.
No differences were observed during the follow-up in TB/HIV
patients evaluated according to the TB clinical forms (data
not shown).
NK Cell Subsets Associated With an
Unfavorable Clinical Outcome
We hypothesized that some association would exist between
the NK cell repertoire changes at W2 of TB treatment
and the patients’ clinical outcomes. The TB/HIV patient
outcomes were classified as favorable in cases of TB treatment
responders or unfavorable in cases of death, which were the
two clinical outcomes observed in our study group. Then,
we calculated the delta between D0 and W2 (1W2−D0) for
all NK cell receptors according to the clinical outcomes. A
significant difference was only observed for the circulating
CD161+ NK cell subset, which presented a significantly higher
1W2−D0 in the TB/HIV patients with an unfavorable clinical
outcome (Figure 9).
NK Cell Degranulation and Cytokine
Production During Treatment Follow-Up
Higher frequencies of CD107a+ NK cells were observed in
TB/HIV patients after stimulation with target cells at all follow-
up visits compared to those of the HIV, TB and HC groups
at D0 despite TB treatment and cART (p < 0.05, data not
shown). As observed at D0, in vitro stimulation of NK cells
with target cells induced higher CD107a+ NK cell expression at
all follow-up visits (Figure 10). CD107a expression in cultures
without stimulation tended to be lower during the follow-
up and became significantly different at W24 (Figure 10; p
= 0.02) compared to that at D0. TB and/or cART treatment
did not appear to impact significantly the NK granulation
capacity after stimulation, at least during the first 24 weeks.
Finally, longitudinal analysis of the ICS frequency among
the TB/HIV patients revealed no changes during follow-up
(data not shown).
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FIGURE 3 | NK cell repertoire before TB and/or cART treatment according to the groups. The results are shown as frequencies of NK cell receptors among the total
NK cell population of TB patients co-infected with HIV (TB/HIV, n = 33), HIV mono-infected individuals (HIV, n = 25), TB-only patients (TB, n = 27) and healthy controls
(HC, n = 25) at D0. The study receptors were C-type lectin receptors (NKG2A, NKG2C, NKG2D, NKp80, CD94, CD69, and CD161), natural cytotoxicity receptors
(NKp30 and NKp46), killer cell immunoglobulin-like receptors (CD158d, CD158a and CD158e1/e2), immunoglobulin-like transcript receptor CD85j, and the
costimulatory CD244 molecule. The results are presented as the median and interquartiles (25th−75th percentile). The data were analyzed using the Mann-Whitney U
test. Significant p-values (p < 0.05) are indicated.
DISCUSSION
In the present work, we investigated the innate blood lymphocyte
profile, specifically NK cells, in TB/HIV patients residing
in Rio de Janeiro city, Brazil, who were cART naive and
evaluated the implications for IRIS development, TB clinical
presentation, and clinical outcomes. The HIV/TB association
poses enormous clinical challenges, starting with an early,
and accurate diagnosis, especially for extrapulmonary cases.
Additionally, this association includes the provision of effective
anti-TB treatment, use of concurrent cART, management of drug
cytotoxicity and IRIS, including its treatment in some cases (46).
In the absence of therapeutic intervention, the NK cell
repertoire is impacted by co-infection, since TB/HIV patients
present alterations in several NK cell receptors that mainly
include decreases in expression. A skewed NK repertoire has
been observed in HIV infection, and these alterations have even
been associated with HIV-1 pathogenesis and disease progression
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FIGURE 4 | Expression of NK cell receptors in IRIS and non-IRIS patients prior to TB treatment and cART. Different frequencies observed between the TB/HIV IRIS
(n = 4) and non-IRIS (n = 29) patients for (A) circulating NK cells and NK subsets expressing (B) NKG2C, (C) NKp80, and (D) CD158a compared to those of the
healthy control (HC, n = 25) group. The results are presented as the median and interquartiles (25th−75th percentile). The data were analyzed using the
Mann-Whitney U test. Significant p-values (p < 0.05) are indicated.
(47, 48). We also observed an impact of HIV infection, since
HIV mono-infected patients also presented alterations in the
NK repertoire frequencies compared with those of the healthy
controls. As reported previously (49–52), modifications in the
NK cell repertoire were observed in HIV-seronegative TB
patients. These results highlighted the complex interactions of
NK cells during TB and/or HIV infection.
In our cohort of TB/HIV patients, only four of 33 (12.1%)
patients developed paradoxical IRIS after cART initiation despite
their severe immunodeficiency (median CD4+ T cell absolute
count: 57 cells/mm3; IQR: 17–144), and high HIV viral loads
(median: 5.64 Log10 copies/mL; IQR: 5.22–5.88) at study
inclusion, besides the early initiation of cART after starting TB
therapy, which are considered significant risk factors for IRIS
development (53, 54). The IRIS frequency in this study is in
accordance with that reported in our previous studies (28, 45),
but differs from the frequencies observed in other populations.
This finding reinforces the concept that the IRIS incidence varies
according to the geographic region (11), and can be explained by
the inclusion of patients with different genetic backgrounds.
Although many studies of HIV/TB patients who developed
IRIS have led to the determination of the most prominent risk
factors for development of this syndrome, such as a low CD4+
T count before cART initiation followed by a successful CD4+
T cell increase (55, 56), the underlying mechanisms responsible
for IRIS have not been clearly defined. One of the most explored
mechanisms is its association with the expansion of antigen-
specific Th1 CD4+ T cells shortly after cART initiation (16),
although subsequent studies questioned whether this association
could be considered truly causal (9). However, elements of
the innate immune system, such as monocytes/macrophages,
dendritic cells (DCs), neutrophils, γδ T lymphocytes, NK
cells, and related soluble factors have also been implicated
in the onset of IRIS, and have been the focus of important
investigations (17, 21, 22, 24, 26, 57).
One clinical trial in Cambodia reported a significantly higher
NK cell degranulation capacity in IRIS patients before cART
and after 2 weeks of TB treatment than in non-IRIS patients,
followed by decreased expression of NK cell activating receptors
(NKp30, NKp46, and NKG2D) at IRIS onset (21). Although
we diagnosed a small number of IRIS cases, we also identified
alterations in the NK cell profile between the IRIS and non-
IRIS patients. A decrease in the frequency of NK cells expressing
NKp80 and NKG2C was observed in the TB/HIV non-IRIS
patients, whereas these receptors were expressed at normal
levels in the IRIS patients compared to those of the healthy
controls. Moreover, the non-IRIS patients also presented a
reduction of NK cells expressing the KIR receptor CD158a.
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FIGURE 5 | Frequencies of NK and γδ T cells according to the TB clinical
presentation. Percentages of (A) circulating γδ T cells (B) NK cells and (C) the
NKp44+ NK subset (among the total NK cells) in the TB/HIV and TB groups
according to pulmonary (PTB: TB/HIV, n = 20; TB, n = 20), lymph node
(LNTB: TB/HIV, n = 6; TB, n = 5) or disseminated (DTB: TB/HIV, n = 5) clinical
presentations of tuberculosis and compared to those of the healthy controls
(HC, n = 25). The results are presented as the median and interquartiles
(25th−75th percentile). The data were analyzed using the Mann-Whitney U
test. Significant p-values (p < 0.05) are indicated.
Recently, NKp80 expression was closely related to NK cell
functional maturity in secondary lymphocyte tissues, suggesting
an important regulatory role for this receptor during the
maturation process at those sites that were potentially related
to the acquisition of NK cell functionality (cytotoxicity and/or
cytokine production) (58). Thus, a loss of this marker could
be related to lower NK cell functions in non-IRIS patients.
However, we did not find a correlation between the degranulation
capacity of NK cells, and expression of the NKp80 marker in
the non-IRIS patients (results not shown). NK cells expressing
the NKG2C activating receptor have been described as an
NK memory-like population against multiple viral infections,
especially cytomegalovirus but also viruses such as simian
immunodeficiency virus (59–62). Moreover, the NKG2C+ NK
population has been suggested to have adaptive properties against
Mtb and to be able to discriminate between latent and active
tuberculosis (increased proportions in latent tuberculosis) (63).
The decrease in NKG2C+ NK cells observed in the non-IRIS
patients suggests lower NK cell recognition of HIV- and/or
TB-infected cells. When considered together with the decrease
in NKp46 expression, the NK cell receptors implicated in
lysis of TB-infected target cells (64) could explain the lower
inflammatory response in this group of patients. In turn,
the CD158a/KIR2DL1 receptor acquires its inhibitory function
during the developmental licensing process of NK cells, and the
absence of this type of receptor during NK cell development has
been associated with less functional competence to respond to
the lack of HLA ligands on a target cell (65, 66). By contrast,
the expression levels of the above-cited receptors in IRIS patients
are similar to those observed in the HC group (higher than in
the non-IRIS patients) and might suggest a more preserved NK
cell repertoire in IRIS patients, who could mount an increased
inflammatory response.
In the present study, we also identified alterations in γδ T
cells in TB/HIV patients similar to those observed in untreated
individuals with chronic HIV-1 infections (67). Higher γδ T cell
frequencies were observed in TB/HIV patients than in the healthy
controls, with the expansion of the γδ T cell subset expressing the
Vδ chain rather than Vδ2 and a low Vδ2+/Vδ2− ratio. Although
not observed in the present study, a higher frequency of Vδ2+
T cells was shown in TB/HIV IRIS patients compared to that
of non-IRIS patients (17). Interestingly, when we analyzed γδ
T cells and their relationship with the clinical presentations of
TB, we identified greater mobilization of γδ T cells in TB/HIV
patients presenting pulmonary TB that was not observed with
either TB/HIV lymph node TB presentation or in the HCs and
was almost higher than that in the HIV-seronegative TB patients.
γδ T cells, especially Vδ2+ T cells, have been widely reported
to play an important role in protective immune responses
to Mtb infection. These cells are expanded early during Mtb
infection and are inclusive in recently acquired latent infection
(68–70). In non-human primates, these cells even attenuate TB
pathology and contain lesions primarily in the infection site of
the lung, with no or reduced TB dissemination (71). However,
in our study, the γδ T population in the TB/HIV patients was
predominantly composed of Vδ2− cells, as previously reported.
In our study, these cells may be engaged in the immune response
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FIGURE 6 | Degranulation capacity of NK cells before TB and/or cART treatment. Frequencies of CD107a+ NK cells at D0 in (A) TB/HIV co-infected patients, HIV
mono-infected (HIV) patients, TB cases (TB) and healthy controls (HCs) after stimulation with the target cell line, (B) in TB/HIV IRIS and non-IRIS patients, and (C)
under non-stimulated (NS) and stimulated (S) conditions with K562 target cells. The results are shown as (A) the median and interquartiles (25th−75th percentile). The
data were analyzed using the Mann-Whitney U test, for intergroup analysis or the Wilcoxon t-test for intragroup analysis. Significant p-values (p < 0.05)
are indicated. ***p < 0.0001.
against pulmonary TB presentation and may be important innate
immune players involved in containment ofMtb infection in the
lungs in the absence of therapeutic intervention.
In relation to another important lymphocyte population
involved in regulatory/effector functions, the iNKT cells (40–42,
72), no significant differences were observed in the present study
when TB/HIV patients were compared with the control groups
(TB, HIV and HC), as well among the TB clinical forms, onset
of IRIS, TB outcomes, or throughout the 6 month of follow-up
under TB-treatment and cART, differing from previous studies
showing reduced frequency of iNKT cells in HIV, TB or TB/HIV
patients compared with healthy controls (73, 74), and between
IRIS and non-IRIS cases (74). Historically, the iNKT cells were
originally identified with the Vα24 and Vβ11 mAb (75, 76), but
it was later shown that the combination of these two selective
reactivities did not formally define this population accurately
(71, 77). In the present study, iNKT cells were accurately analyzed
as Vα24Jα18+ cells, using the monoclonal antibody 6B11, in the
context of the CD3+CD56+ population, as supported by vast
literature (40–42, 78). However, it has been further shown that
not all iNKT cells are CD56+ (72). In this sense, we re-analyzed
the Vα24Jα18+ cells in the context of the CD3+ population and,
similarly, the obtained results did not show significant differences
in the frequency of this population among the studied groups
and/or clinical conditions.
We also investigated the in vitro degranulation and cytokine
production potential of NK cells from TB/HIV patients. We
observed a higher degranulation capacity in TB/HIV patients
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FIGURE 7 | Frequencies of NK cells producing intracellular cytokines under in vitro stimulation. Percentages of IFN-γ+, TNF+, TGF-β+, and IL-10+ NK cells after
stimulation with target cells at D0 in (A) the TB/HIV co-infected, HIV mono-infected (HIV), TB-only (TB) and healthy control (HC) groups, (B) according to the TB clinical
presentation as pulmonary (PTB), lymph node (LNTB), and disseminated TB in TB/HIV co-infected patients and for PTB and LNTB in the TB-only patients. The results
are presented as the median and interquartiles (25th−75th percentile). The data were analyzed using the Mann-Whitney U test. Significant p-values (p < 0.05) are
indicated.
FIGURE 8 | Expression of NK cell receptors during follow-up in the TB/HIV co-infected patients. Expression of different NK receptors in the TB/HIV patients before
and after treatment intervention (anti-TB at day 0 and cART at week 2) and at weeks (W) 2, 6, 10, 14, and 24. The results are represented as the median and
interquartiles (25th−75th percentile). The data were analyzed using the Wilcoxon t-test. Significant p-values (p < 0.05) are indicated.
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than in the other groups. Different from the results obtained in
the study in Cambodia (21), we did not observe differences in
the CD107a+ NK cell frequencies between the IRIS and non-
IRIS patients after in vitro stimulation with a target cell line or
not. However, the results from Cambodia were obtained after
2 weeks of TB treatment and before cART initiation, whereas
in our study, the degranulation capacity was assessed before
any treatment intervention. Moreover, we did not detect an
increase in degranulation capacity of NK cells after 2 weeks of
TB treatment or later (during the follow-up under cART and TB
treatment). Although in vivo NK cell activation was observed
in our study groups (based on an increase in some activation
markers and degranulation without any activation) similar to
that in the Capri NK study (21), we should consider other
factors, such as differences either on genetic backgrounds and/or
local endemic pathogens able to stimulate innate immunity.
Interestingly, spontaneous CD107a+ expression was significantly
lower in the IRIS than in the non-IRIS patients. The spontaneous
NK cell degranulation observed in the non-IRIS TB/HIV patients
may result from a skewed NK repertoire. Consistent with
this observation, the lower frequency of CD158a+ NK cells
observed in these patients could be related to a more immature
profile among these individuals compared to the more regulated
and lower CD107a+ NK cell expression levels detected in the
IRIS patients.
Although NK cells regulate immune responses through
cytokines secretion (79), there are few reports describing the
NK regulatory cytokine secretion patterns in TB/HIV patients
(80). In our study, TB/HIV patients showed a lower frequency
of intracellular IFN-γ-producing NK cells compared to the HC
group, as well as of TNF- compared to HIV, TB, and HC groups.
On the other hand, the frequency TGF-β- or IL-10-producing
NK cells in the TB/HIV group was significantly higher than that
in the HIV and TB patients. These results reflect the interplay
between pro-inflammatory and regulatory cytokines in TB/HIV
patients and could indicate the establishment of regulatory
mechanisms to control the exacerbated inflammatory response
by the innate immune system in TB/HIV patients. Similar to our
results, lower frequency of NK intracellular pro-inflammatory
cytokines, IFN-γ and TNF-, were observed in TB/HIV patients
from India compared to healthy controls (80).
We observed that several NK cell receptors were enhanced
during the two first weeks of TB treatment. There is no
report of NK cell repertoire modifications after 2 weeks of TB
treatment in patients infected with TB/HIV or TB alone. Only
one communication has studied modifications of NK receptors
after 6 months of TB treatment in pulmonary TB (51). Although
recovery of NK cell function was observed, perturbations of the
NK cell repertoire were still present at the endpoint of the study
(51). We do not have a full explanation for this discrepancy, but
genetic factors may be differently implicated in these cohorts.
For the TB/HIV study group, cART was started in the second
week of TB treatment, and the patients were followed in the
study until the end of TB treatment at week 24. Despite the
CD4+ T cell recovery and control of HIV-1 replication, cART
had a low or no impact on the NK cell repertoire. Similarly, other
reports were not able to show the recovery of NK cells despite
FIGURE 9 | Distribution of 1W2−D0 for CD161
+ NK cells. Frequencies
obtained for the differences in CD161+ NK cell expression between D0 and
week 2 (W2) in TB/HIV patients analyzed based on favorable (n = 26) or
unfavorable (n = 5) clinical outcomes. The results are presented as the median
and interquartiles (25th−75th percentile). The data were analyzed using the
Mann-Whitney U test. A significant p-value (p < 0.05) is indicated.
the long cART follow-up period (up to 85 months), with viral
replication suppression and increased levels on CD4+ T counts
(9). Moreover, recovery of the NK cell repertoire during cART
has been described (81), but the restoration takes more time
than the recovery of CD4+ T cells, in particular when the CD4+
T- counts are very low, like in our study. Our limited follow-
up did not allow us the observation of late modifications in the
NK cell repertoire and functions. However, early modifications
induced during TB treatment alone showed that patients with an
unfavorable outcome presented a higher frequency of CD161+
NK cells than patients with a favorable TB recovery outcome.
CD161 is a marker of human IL-17-producing T cell subsets,
and its expression marks pro-inflammatory NK cells with high
cytokine responsiveness that may contribute to inflammatory
disease pathogenesis (82–84). Induction of modifications such
as those reported here was observed after IL-10 treatment of
PBMCs, including induction of higher CD161 marker expression
on NK cells (84, 85). Although the treatment schedule used in
this study was related to a reduced risk of death (52), five of
the 33 HIV/TB patients presented this unfavorable outcome, and
the NK cells with a pro-inflammatory profile observed in these
TB/HIV patients could have participated in this process.
Our study has some limitations. The main limitation was
the low numbers of IRIS TB/HIV patients, patients with
lymph node and disseminated TB presentation, and unfavorable
outcomes/death, which possibly were due to the low number
of TB/HIV patients recruited during the study period even
though the city of Rio de Janeiro is an endemic region for
tuberculosis. Indeed, the recruitment of a larger number of
the TB/HIV patients, as initially planned, was not achieved
along the period of the study support, possibly due to the
implementation by the Brazilian Ministry of Health of the free
early access to antiretrovirals in the recent years, independently
of the CD4+ T-cell counts and clinical conditions, and also
INH prophylaxis for some HIV-infected patients, restricting
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FIGURE 10 | Degranulation capacity of NK cells during the study follow-up. Frequencies of CD107a+ NK cells detected in TB/HIV co-infected patients before and
after treatment intervention under non-stimulated (NS) or stimulated (S) conditions with K562 target cells. The data were analyzed using the Wilcoxon t-test.
Significant p-values (p < 0.05) are indicated. ***p < 0.0001.
our access to participants with CD4+ T-cell counts <200
cells/mm3, a inclusion criteria to the TB/HIV and the HIV
patients (86). Because of the sample size, multivariate analyses
were not carried out, which restricted the statistical analysis
to univariate analyses. Future investigations are necessary
to prove the concepts observed and discussed here, such
as the association of IRIS development in TB/HIV patients
with a more conserved and specialized NK cell profile, the
relationship of γδ T cells with the immune response in patients
with pulmonary TB presentation, and the involvement of
pro-inflammatory NK cells with an unfavorable outcome of
TB/HIV coinfection.
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CD3+CD56+ vs. Vα24Jα18+ dot plot defined the iNKT cells. (B) Comparative
analysis of iNKT cells among the TB/HIV (n = 33), HIV (n = 25), TB (n = 27), and
HC (n = 25) groups, before any therapeutic intervention, based on the
CD3+CD56+Vα24Jα18+ or CD3+ Vα24Jα18+ populations.
Supplementary Table 1 | Clinical characteristics of the TB/HIV IRIS patients.
Supplementary Table 2 | Medians and interquartile ranges (IQRs) of the
circulating NK cell repertoire frequencies.
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